Table 3.
Summary of current TBK1 inhibitors
| Compounds | Targets | Reference | Clinical Trial |
|---|---|---|---|
| Amlexanox (AMX) | TBK1/IKKε | [40, 246–252] | NCT01842282; NCT01975935 |
| AZ13102909 (AZ909) | TBK1 | [223] | |
| BAY-985 | TBK1/IKKε | [253] | |
| BX795 |
TBK1/IKKε Aurora B NUAK1 PDK1 |
[254–256] | |
| Compound I | TBK1/IKKε | [244] | |
| Compound II | TBK1/IKKε | [229, 257] | |
| DMX-14 | TBK1/IKKε | [258] | |
| GSK8612 | TBK1 | [259] | |
| MDK10496 | TBK1/IKKε | [260] | |
| MMB/CYT387/GS-0387 |
TBK1/IKKε ACVR1 ALK2 JAK1/2 |
[231, 261–267] | NCT02101021; NCT02206763; NCT02258607; NCT04173494/MOMENTUM; NCT01969838/SIMPLIFY1; NCT02101268 |
| MPI-0485520 | TBK1/IKKε | [268] | |
| MRT67307 |
TBK1/IKKε ULK1/2 |
[99] | |
| MRT68601 | TBK1 | [255] | |
| UNC6587/Cereblon-TBK1 PROTAC | TBK1 | [81] | |
| 15a |
TBK1/IKKε Aurora A GSK3β Aurora A PDK1 |
[269] | |
| 200A | TBK1/IKKε | [270] | |
| 3i/pVHL-TBK1 PROTAC | TBK1 | [271] |